EMA Authorised: Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen) (aripiprazole) — Mylan Pharmaceuticals Limited

View source ↗

Summary

EMA authorised Aripiprazole Mylan Pharma (generic aripiprazole) for schizophrenia and bipolar disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• Aripiprazole Mylan Pharma (aripiprazole)

Snippet

Status: Authorised. Therapeutic area: Schizophrenia;Bipolar Disorder. MAH: Mylan Pharmaceuticals Limited. Decision date: 22/01/2026